| 摘要 |
Disclosed is polymorphic form kappa of rifaximin, wherein form kappa of rifaximin is a variable isopropanol solvate that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2&thetas; at (6.45 - 6.67) ± 0.20, (6.83 - 6.94) ± 0.20, (7.52 - 7.56) ± 0.20, (7.68 - 7.78) ± 0.20 and (8.30 - 8.34) ± 0.20. Further disclosed is a pharmaceutical composition comprising the form kappa as defined above and a pharmaceutically acceptable carrier, wherein preferably the composition is formulated as coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets or powders in sealed packets. |
